• Silexion Therapeutics posted a net loss of USD 2.73 million, widening 58.8% from the year-ago quarter.
• Operating loss widened to USD 2.75 million as operating expenses climbed to USD 2.75 million.
• Research and development expense more than doubled to USD 1.37 million, driven by higher subcontractor and consultant spending tied to toxicology studies, product development, and GMP manufacturing ahead of a planned human clinical trial expected in Q2 2026, subject to regulatory clearance.
• General and administrative expense rose 27.3% to USD 1.38 million on higher professional services costs related to operating as a public company.
• Cash and cash equivalents totaled USD 2.4 million at March 31, 2026, with management saying liquidity covers only several months and additional capital will be needed within 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-002744), on May 15, 2026, and is solely responsible for the information contained therein.